Status:
COMPLETED
Magnesium Supplementation in Diabetic Nephropathy
Lead Sponsor:
Ain Shams University
Conditions:
Diabetic Nephropathies
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
Higher prevalence of hypomagnesaemia in diabetic patients with nephropathy was compared to those without nephropathy. Serum magnesium levels were significantly inversely correlated with serum creatini...
Detailed Description
Diabetic nephropathy is a serious kidney-related complication of type 1 diabetes and type 2 diabetes. It is also called diabetic kidney disease. Up to 40 percent of people with diabetes eventually dev...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Type I or II diabetic patientCKD stage 3 ( eGFR = 30 - 59 ml/min) or stage 4 ( eGFR 15-29 ml/min)
- Proteinuria 30-300 mg/dl (microalbuminuria)
- Low SMg levels (1.4-1.9 mg/dL; 0.58-0.78 mM) to normal (1.7-2.4 mg/dL; 0.7 -1.1 mmol/L; 1.4-2.0 mEq/L).
- Life expectancy \>12 months.
- Women of child-bearing age should be using contraceptives as Hormonal contraceptive or Intra-uterine device.
Exclusion
- Kidney donor recipient.
- Current treatment with Mg supplements.
- Any condition impairing intestinal absorption of Mg (e.g: chronic pancreatitis, short bowel syndrome)
- Active malignancy.
- Pregnancy or breastfeeding.
- Cardiac Arrythmias.
- Allergy towards the Mg supplement.
- Participation in other interventional trials.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03824379
Start Date
June 1 2019
End Date
March 1 2020
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Abbasseia, Egypt, 12345